John MacFarlane
President & CEO, London Health Sciences Foundation
Topic: A message of welcome.
WATCH NOW
A VIRTUAL ANNOUNCEMENT
The below announcement is a presentation honouring a second transformational gift of $3M from Archie and Irene Verspeeten to the Archie and Irene Verspeeten Clinical Genome Centre.
In this virtual announcement, you will hear from world-leading cancer researchers and clinicians about how the Archie and Irene Verspeeten Clinical Genome Centre is revolutionizing treatment options for patients with diseases linked to genetics.
SPEAKERS
Slider item
Dr. Jackie Schleifer Taylor
President & CEO, London Health Sciences Centre
Topic: A message of welcome.
Dr. Daniel Breadner
Assistant Professor and Medical Oncologist, Molecular Tumour Board Chair
Topic: POWER Study
Dr. Stephen Welch
Medical Oncologist, Chair, Division of Medical Oncology
MD FRCPC
Topic: POWER Study
Jennefer Masters
Director, Molecular Diagnostics, Verspeeten Clinical Genome Centre, Partnerships & Innovation
Topic: Policy and change in health care.
Dr. Bekim Sadikovic
Clinical and Scientific Director, Verspeeten Clinical Genome Centre
Program Head, Molecular Diagnostics, Pathology and Laboratory Medicine
London Health Sciences Centre and St. Joseph’s Health Care London
Professor, Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, Western University
Topic: Beyond Genomics
ABOUT the Archie and Irene Verspeeten Clinical Genome Centre
No two people are the same and genetic differences can mean even if a treatment works for one patient, it may not work for another.
The Archie and Irene Verspeeten Clinical Genome Centre aims to use genomic profiling to help create personalized treatment that will improve outcomes for patients with diseases linked to genetics such as cancer, epilepsy, neuromuscular disorders and developmental disabilities.
It is the first of its kind in Canada.
Contact us at 519.685.8409 | foundation@lhsc.on.ca | lhsf.ca